Enhanced antitumor efficacy of a vascular disrupting agent combined with an antiangiogenic in a rat liver tumor model evaluated by multiparametric MRI

PLoS ONE

Volumn 7, Issue 7, 2012, Pages

  Chen, Feng ^a,b   Feng, Yingmei ^c   Zheng, Kaier ^d   de Keyzer, Frederik ^a   Li, Junjie ^a   Feng, Yuanbo ^a   Cona, Marlein Miranda ^a   Wang, Huaijun ^a   Jiang, Yansheng ^a   Yu, Jie ^a   Marchal, Guy ^a   Verfaillie, Catherine ^c   de Geest, Bart ^e   Oyen, Raymond ^a   Ni, Yicheng ^a  

^a UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^b SOUTHEAST UNIVERSITY   (China)

^c UNIVERSITY OF LEUVEN   (Belgium)

^d NANJING MEDICAL UNIVERSITY   (China)

^e UNIVERSITY OF LEUVEN   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOGENESIS INHIBITOR; N ACETYLCOLCHINOL PHOSPHATE; STROMAL CELL DERIVED FACTOR 1ALPHA; THALIDOMIDE; VASCULAR TARGETING AGENT;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BLOOD VESSEL PERMEABILITY; CANCER GRAFT; CELL DEATH; CONTROLLED STUDY; DIFFUSION COEFFICIENT; DRUG EFFICACY; DRUG POTENTIATION; ENDOTHELIAL PROGENITOR CELL; HEMODYNAMICS; HISTOPATHOLOGY; IN VIVO STUDY; LINEAR REGRESSION ANALYSIS; LIVER TUMOR; MULTIPARAMETRIC MAGNETIC RESONANCE IMAGING; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; RAT; REPEATED DRUG DOSE; TUMOR CELL; TUMOR GROWTH; TUMOR MODEL; TUMOR VASCULARIZATION;

ANGIOGENESIS INHIBITORS; ANIMALS; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APOPTOSIS; CHEMOKINE CXCL12; ENDOTHELIAL CELLS; HUMANS; LIVER NEOPLASMS; MAGNETIC RESONANCE IMAGING; MICROCIRCULATION; NECROSIS; ORGANOPHOSPHORUS COMPOUNDS; RATS; STEM CELLS; THALIDOMIDE;

ANIMALIA; RATTUS;

EID: 84864015478     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0041140     Document Type: Article

References (38)

1. Denekamp J, Hobson B, (1982) Endothelial-cell proliferation in experimental tumours. Br J Cancer 46: 711-20.
2. Tozer GM, Kanthou C, Baguley BC, (2005) Disrupting tumour blood vessels. Nat Rev Cancer 5: 423-35.
3. Dark GG, Hill SA, Prise VE, Tozer GM, Pettit GR, et al. (1997) Combretastatin A-4, an agent that displays potent and selective toxicity toward tumor vasculature. Cancer Res 57: 1829-34.
4. Schwartz EL, (2009) Antivascular actions of microtubule-binding drugs. Clin Cancer Res 15: 2594-601.
5. Siemann DW, Shi W, (2004) Efficacy of combined antiangiogenic and vascular disrupting agents in treatment of solid tumors. Int J Radiat Oncol Biol Phys 60: 1233-40.
6. Kanthou C, Tozer GM, (2009) Microtubule depolymerizing vascular disrupting agents: novel therapeutic agents for oncology and other pathologies. Int J Exp Pathol 90: 284-94.
7. Siemann DW, (2011) The unique characteristics of tumor vasculature and preclinical evidence for its selective disruption by Tumor-Vascular Disrupting Agents. Cancer Treat Rev 37: 63-74.
8. Kobayashi H, Longmire MR, Ogawa M, Choyke PL, Kawamoto S, (2010) Multiplexed imaging in cancer diagnosis: applications and future advances. Lancet Oncol 11: 589-95.
9. Padhani AR, Miles KA, (2010) Multiparametric imaging of tumor response to therapy. Radiology 256: 348-64.
10. Blakey DC, Ashton SE, Westwood FR, Walker M, Ryan AJ, (2002) ZD6126: a novel small molecule vascular targeting agent. Int J Radiat Oncol Biol Phys 54: 1497-502.
11. Lin YC, Shun CT, Wu MS, Chen CC, (2006) A novel anticancer effect of thalidomide: inhibition of intercellular adhesion molecule-1-mediated cell invasion and metastasis through suppression of nuclear factor-kappaB. Clin Cancer Res 12: 7165-73.
12. Freter CE, Perry MC, (2008) Systemic Therapy. In: Abeloff MD, Armitage JO, Niederhuber JE, Kastan MB, McKenna WG, editors. pp. 449-483 editors. Abeloff's Clinical oncology.Churchill Livingstone Elsevier: Philadelphia.
13. Rajkumar SV, Witzig TE, (2000) A review of angiogenesis and antiangiogenic therapy with thalidomide in multiple myeloma. Cancer Treat Rev 26: 351-62.
14. Ansiaux R, Baudelet C, Jordan BF, Beghein N, Sonveaux P, et al. (2005) Thalidomide radiosensitizes tumors through early changes in the tumor microenvironment. Clin Cancer Res 11: 743-50.
15. Chen F, De Keyzer F, Ni Y, (2011) Cancer Models- Multiparametric Applications of Clinical MRI in Rodent Hepatic Tumor Model. In: Schroeder L, Faber C, editors. pp. 489-507 editors. In vivo MR Imaging: Methods and Protocols.Humana Press (part of the Springer publishing group): Berlin.
16. Chen F, Sun X, De Keyzer F, Yu J, Peeters R, et al. (2006) Liver tumor model with implanted rhabdomyosarcoma in rats: MR imaging, microangiography, and histopathologic analysis. Radiology 239: 554-62.
17. Kivivuori SM, Riikonen P, Valanne L, Lonnqvist T, Saarinen-Pihkala UM, (2011) Antiangiogenic combination therapy after local radiotherapy with topotecan radiosensitizer improved quality of life for children with inoperable brainstem gliomas. Acta Paediatr 100: 134-8.
18. Shaked Y, Tang T, Woloszynek J, Daenen LG, Man S, et al. (2009) Contribution of granulocyte colony-stimulating factor to the acute mobilization of endothelial precursor cells by vascular disrupting agents. Cancer Res 69: 7524-8.
19. Feng Y, Jacobs F, Van Craeyveld E, Brunaud C, Snoeys J, et al. (2008) Human ApoA-I transfer attenuates transplant arteriosclerosis via enhanced incorporation of bone marrow-derived endothelial progenitor cells. Arterioscler Thromb Vasc Biol 28: 278-83.
20. Chen F, De Keyzer F, Wang H, Vandecaveye V, Landuyt W, et al. (2007) Diffusion weighted imaging in small rodents using clinical MRI scanners. Methods 43: 12-20.
21. Tofts PS, (1997) Modeling tracer kinetics in dynamic Gd-DTPA MR imaging. J Magn Reson Imaging 7: 91-101.
22. Kiessling F, Jugold M, Woenne EC, Brix G, (2007) Non-invasive assessment of vessel morphology and function in tumors by magnetic resonance imaging. Eur Radiol 17: 2136-48.
23. Ostergaard L, Weisskoff RM, Chesler DA, Gyldensted C, Rosen BR, (1996) High resolution measurement of cerebral blood flow using intravascular tracer bolus passages. Part I: Mathematical approach and statistical analysis. Magn Reson Med 36: 715-25.
24. Shaked Y, Ciarrocchi A, Franco M, Lee CR, Man S, et al. (2006) Therapy-induced acute recruitment of circulating endothelial progenitor cells to tumors. Science 313: 1785-7.
25. van Heeckeren WJ, Sanborn SL, Narayan A, Cooney MM, McCrae KR, et al. (2007) Complications from vascular disrupting agents and angiogenesis inhibitors: aberrant control of hemostasis and thrombosis. Curr Opin Hematol 14: 468-80.
26. Wang H, Sun X, Chen F, De Keyzer F, Yu J, et al. (2009) Treatment of rodent liver tumor with combretastatin a4 phosphate: noninvasive therapeutic evaluation using multiparametric magnetic resonance imaging in correlation with microangiography and histology. Invest Radiol 44: 44-53.
27. Lang P, Wendland MF, Saeed M, Gindele A, Rosenau W, et al. (1998) Osteogenic sarcoma: noninvasive in vivo assessment of tumor necrosis with diffusion-weighted MR imaging. Radiology 206: 227-35.
28. Kim JJ, Tannock IF, (2005) Repopulation of cancer cells during therapy: an important cause of treatment failure. Nat Rev Cancer 5: 516-25.
29. Dachs GU, Steele AJ, Coralli C, Kanthou C, Brooks AC, et al. (2006) Anti-vascular agent Combretastatin A-4-P modulates hypoxia inducible factor-1 and gene expression. BMC Cancer 6: 280.
30. D'Amato RJ, Loughnan MS, Flynn E, Folkman J, (1994) Thalidomide is an inhibitor of angiogenesis. Proc Natl Acad Sci U S A 91: 4082-5.
31. Sleijfer S, Kruit WH, Stoter G, (2004) Thalidomide in solid tumours: the resurrection of an old drug. Eur J Cancer 40: 2377-82.
32. Reck M, Gatzemeier U, (2010) Targeted therapies: Thalidomide in lung cancer therapy-what have we learned? Nat Rev Clin Oncol 7: 134-5.
33. Figg WD, Li H, Sissung T, Retter A, Wu S, et al. (2007) Pre-clinical and clinical evaluation of estramustine, docetaxel and thalidomide combination in androgen-independent prostate cancer. BJU Int 99: 1047-55.
34. Thoeny HC, De Keyzer F, Chen F, Vandecaveye V, Verbeken EK, et al. (2005) Diffusion-weighted magnetic resonance imaging allows noninvasive in vivo monitoring of the effects of combretastatin a-4 phosphate after repeated administration. Neoplasia 7: 779-87.
35. Jain RK, (2005) Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science 307: 58-62.
36. Lebrin F, Srun S, Raymond K, Martin S, van den Brink S, et al. (2010) Thalidomide stimulates vessel maturation and reduces epistaxis in individuals with hereditary hemorrhagic telangiectasia. Nat Med 16: 420-8.
37. Winkler F, Kozin SV, Tong RT, Chae SS, Booth MF, et al. (2004) Kinetics of vascular normalization by VEGFR2 blockade governs brain tumor response to radiation: role of oxygenation, angiopoietin-1, and matrix metalloproteinases. Cancer Cell 6: 553-63.
38. Siemann DW, (2011) The unique characteristics of tumor vasculature and preclinical evidence for its selective disruption by Tumor-Vascular Disrupting Agents. Cancer Treat Rev 37: 63-74.